Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era

Fernando Barroso Duarte, MD, Federal University of Ceara, Fortaleza, Brazil, discusses the relevance of the Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes (MDS) during stem cell transplantation (SCT) in the molecular classification era. Prof. Barroso Duarte outlines the results of a study showing that in countries where access to molecular data is limited, the IPSS-R can still be used to risk stratify patients. Prof. Barroso Duarte also highlights the importance of risk stratifying patients prior to SCT, and of better defining how the molecular-IPSS (IPSS-M) can be used in clinical practice. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.